EGFR and breast carcinoma: Although AXL has been shown previously to relay secondary resistance to EGFR and HER targeted therapies in a subset of breast and lung cancers16,22,23,25, a marked increase of AXL expression and stability in our small cohort of relapsed breast cancer tumors was unexpected.